Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
Other Sizes |
|
Purity: ≥98%
Heparin sodium (150,160,170,180unit/mg) is a sulfated polysaccharide that is a member of the glycosaminoglycan family. It interacts with various proteins to perform a variety of significant biological functions. Because heparin can quicken the pace at which antithrombin inhibits serine proteases in the blood coagulation cascade, it is frequently used as an anticoagulant medication. Heparin and heparan sulfate, which share structural similarities, are complex linear polymers consisting of a mixture of chains with varying lengths and sequences.
Targets |
Antithrombin III
|
|
---|---|---|
ln Vitro |
Heparin is a potent anticoagulant medication because it can quicken the pace at which antithrombin inhibits serine proteases in the cascade of blood coagulation. Heparin and heparan sulfate, which share structural similarities, are complex linear polymers consisting of a mixture of chains with varying lengths and sequences. Peptides with a corresponding binding site that has a high positive charge density exhibit the strongest interactions with heparin. Along the polysaccharide backbone, heparin and heparan sulfate primarily show linear helical secondary structures with carboxyl and sulfo groups exhibited at specific orientations and intervals. Heparin and DNA are both highly charged linear polymers that exhibit polyelectrolyte behavior. Heparin is thought to work as an anticoagulant mainly by interacting with AT III to improve AT-III-mediated inhibition of blood coagulation factors, such as factor Xa and thrombin. The ternary complex formed by heparin's binding to AT III and thrombin increases the bimolecular rate constant for thrombin inhibition by a factor of 2000. The main place to find heparin is in the tissue mast cell granules, which are intimately related to the immune response. Heparin interacts extensively with FGFR-1 and FGF-2 to stabilize the binding of these two proteins. Additionally, heparin interacts with FGFR-1 of the nearby FGF–FGFR complex, which appears to encourage FGFR dimerization[1].
|
|
ln Vivo |
|
|
Enzyme Assay |
Heparin, a sulfated polysaccharide belonging to the family of glycosaminoglycans, has numerous important biological activities, associated with its interaction with diverse proteins. Heparin is widely used as an anticoagulant drug based on its ability to accelerate the rate at which antithrombin inhibits serine proteases in the blood coagulation cascade. Heparin and the structurally related heparan sulfate are complex linear polymers comprised of a mixture of chains of different length, having variable sequences. Heparan sulfate is ubiquitously distributed on the surfaces of animal cells and in the extracellular matrix. It also mediates various physiologic and pathophysiologic processes. Difficulties in evaluating the role of heparin and heparan sulfate in vivo may be partly ascribed to ignorance of the detailed structure and sequence of these polysaccharides. In addition, the understanding of carbohydrate-protein interactions has lagged behind that of the more thoroughly studied protein-protein and protein-nucleic acid interactions. The recent extensive studies on the structural, kinetic, and thermodynamic aspects of the protein binding of heparin and heparan sulfate have led to an improved understanding of heparin-protein interactions. A high degree of specificity could be identified in many of these interactions. An understanding of these interactions at the molecular level is of fundamental importance in the design of new highly specific therapeutic agents. This review focuses on aspects of heparin structure and conformation, which are important for its interactions with proteins. It also describes the interaction of heparin and heparan sulfate with selected families of heparin-binding proteins [1].
|
|
Animal Protocol |
C57BL/6J mice
100, 500, or 2500 units/kg i.p. |
|
References |
Molecular Formula |
(C12H16NS2NA3)20
|
|
---|---|---|
Molecular Weight |
6000-20000
|
|
CAS # |
9041-08-1
|
|
Related CAS # |
Heparin sodium salt;9041-08-1;Heparin Lithium salt;9045-22-1;Heparin;9005-49-6
|
|
Appearance |
White to off-white solid
|
|
SMILES |
C1N(CN(CN1CCO)CC[O-])CCO.[Na+]
|
|
InChi Key |
YOMTXLQWRQUKAK-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C9H20N3O3.Na/c13-4-1-10-7-11(2-5-14)9-12(8-10)3-6-15;/h13-14H,1-9H2;/q-1;+1
|
|
Chemical Name |
sodium;2-[3,5-bis(2-hydroxyethyl)-1,3,5-triazinan-1-yl]ethanolate
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
J Biol Chem . 2016 Jan 22;291(4):1652-1663. td> |
J Biol Chem . 2016 Jan 22;291(4):1652-1663. td> |
J Biol Chem . 2016 Jan 22;291(4):1652-1663. td> |